(S)-6-methoxy-N-(2-((R)-1-methylpyrrolidin-3-yloxy)-4-(1H-pyrazol-4-yl)phenyl)chroman-3-carboxamide

ID: ALA3221811

Chembl Id: CHEMBL3221811

PubChem CID: 90668077

Max Phase: Preclinical

Molecular Formula: C25H28N4O4

Molecular Weight: 448.52

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1O[C@@H]1CCN(C)C1)CO2

Standard InChI:  InChI=1S/C25H28N4O4/c1-29-8-7-21(14-29)33-24-11-16(19-12-26-27-13-19)3-5-22(24)28-25(30)18-9-17-10-20(31-2)4-6-23(17)32-15-18/h3-6,10-13,18,21H,7-9,14-15H2,1-2H3,(H,26,27)(H,28,30)/t18-,21+/m0/s1

Standard InChI Key:  OZBHPAKTNOSDFP-GHTZIAJQSA-N

Associated Targets(Human)

ROCK2 Tclin Rho-associated protein kinase 2 (6206 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDC42BPA Tchem Serine/threonine-protein kinase MRCK-A (2525 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rock2 Rho-associated protein kinase 2 (125 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 448.52Molecular Weight (Monoisotopic): 448.2111AlogP: 3.36#Rotatable Bonds: 6
Polar Surface Area: 88.71Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 12.19CX Basic pKa: 8.43CX LogP: 2.72CX LogD: 1.65
Aromatic Rings: 3Heavy Atoms: 33QED Weighted: 0.60Np Likeness Score: -1.05

References

1. Chen YT, Vojkovsky T, Fang X, Pocas JR, Grant W, Handy AMW, Schroter T, LoGrasso P, Bannister TD, Feng Y.  (2011)  Asymmetric synthesis of potent chroman-based Rho kinase (ROCK-II) inhibitors,  (1): [10.1039/C0MD00194E]

Source